QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
Log in
NASDAQ:LUMO

Lumos Pharma Stock Forecast, Price & News

$13.44
-0.83 (-5.82 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.83
Now: $13.44
$14.50
50-Day Range
$13.60
MA: $17.78
$22.13
52-Week Range
$6.74
Now: $13.44
$36.72
Volume27,373 shs
Average Volume37,104 shs
Market Capitalization$111.51 million
P/E RatioN/A
Dividend YieldN/A
Beta1.69
Lumos Pharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency. The company has a licensing agreement with Ellipses Pharma Limited for the development of and rights to commercialize nanoparticle formulations of two therapeutics for oncology indications. Lumos Pharma, Inc. was founded in 2011 and is headquartered in Austin, Texas.
Lumos Pharma logo

Headlines

Lumos Pharma Announces Changes to its Board of Directors
February 16, 2021 |  finance.yahoo.com
Is Lumos Pharma (LUMO) A Good Stock To Buy Now?
November 30, 2020 |  finance.yahoo.com
Lumos Pharma to Participate in December Investor Conferences
November 23, 2020 |  finance.yahoo.com
Lumos Pharma EPS beats by $0.86, misses on revenue
November 10, 2020 |  seekingalpha.com
Lumos Pharma Inc to Host Earnings Call
November 10, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LUMO
CUSIPN/A
CIKN/A
Phone512-215-2630
Employees28
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$940,000.00
Book Value$19.03 per share

Profitability

Net Income$-42,990,000.00
Net Margins-2,053.30%

Miscellaneous

Market Cap$111.51 million
Next Earnings Date3/9/2021 (Confirmed)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.61 out of 5 stars

Medical Sector

344th out of 1,969 stocks

Pharmaceutical Preparations Industry

165th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$13.44
-0.83 (-5.82 %)
(As of 03/4/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LUMO News and Ratings via Email

Sign-up to receive the latest news and ratings for LUMO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Lumos Pharma (NASDAQ:LUMO) Frequently Asked Questions

Is Lumos Pharma a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lumos Pharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Lumos Pharma stock.
View analyst ratings for Lumos Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Lumos Pharma?

Wall Street analysts have given Lumos Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Lumos Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Lumos Pharma's next earnings date?

Lumos Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Lumos Pharma
.

How can I listen to Lumos Pharma's earnings call?

Lumos Pharma will be holding an earnings conference call on Tuesday, March 9th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Lumos Pharma's earnings last quarter?

Lumos Pharma, Inc. (NASDAQ:LUMO) announced its quarterly earnings data on Tuesday, November, 10th. The company reported $0.21 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.65) by $0.86. The firm earned $0.07 million during the quarter, compared to analyst estimates of $7.80 million. Lumos Pharma had a negative trailing twelve-month return on equity of 10.58% and a negative net margin of 2,053.30%.
View Lumos Pharma's earnings history
.

What price target have analysts set for LUMO?

5 equities research analysts have issued twelve-month price objectives for Lumos Pharma's shares. Their forecasts range from $12.00 to $51.00. On average, they anticipate Lumos Pharma's stock price to reach $31.00 in the next year. This suggests a possible upside of 130.7% from the stock's current price.
View analysts' price targets for Lumos Pharma
or view top-rated stocks among Wall Street analysts.

Who are Lumos Pharma's key executives?

Lumos Pharma's management team includes the following people:
  • Mr. Richard J. Hawkins, Founder, Chairman, CEO & Pres (Age 72)
  • Mr. Carl W. Langren, Chief Financial Officer (Age 66)
  • Dr. John C. McKew, COO & Chief Scientific Officer (Age 57)
  • Lisa Miller, Director of Investor Relations
  • Mr. Bradley J. Powers J.D., Gen. Counsel (Age 42)
  • Mr. Aaron Schuchart B.B.A., CPA, M.B.A., Chief Bus. Officer (Age 56)
  • Dr. Eugene P. Kennedy F.A.C.S., M.D., FACS, Chief Medical Officer (Age 52)
  • Ms. Lori D. Lawley CPA, Sr. VP of Fin. & Corp. Controller (Age 37)

Who are some of Lumos Pharma's key competitors?

What other stocks do shareholders of Lumos Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lumos Pharma investors own include Advanced Micro Devices (AMD), (NCLH), Northern Oil and Gas (NOG), Agilent Technologies (A), Air Lease (AL), Ampio Pharmaceuticals (AMPE), Bionano Genomics (BNGO), Chimerix (CMRX), Compagnie de Saint-Gobain (CODYY) and CorMedix (CRMD).

What is Lumos Pharma's stock symbol?

Lumos Pharma trades on the NASDAQ under the ticker symbol "LUMO."

Who are Lumos Pharma's major shareholders?

Lumos Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (3.72%), Opaleye Management Inc. (3.39%), Wells Fargo & Company MN (1.42%), ExodusPoint Capital Management LP (0.45%), Investors Financial Group LLC (0.22%) and Bank of New York Mellon Corp (0.21%).
View institutional ownership trends for Lumos Pharma
.

Which institutional investors are selling Lumos Pharma stock?

LUMO stock was sold by a variety of institutional investors in the last quarter, including Investors Financial Group LLC.
View insider buying and selling activity for Lumos Pharma
or view top insider-selling stocks.

Which institutional investors are buying Lumos Pharma stock?

LUMO stock was bought by a variety of institutional investors in the last quarter, including Opaleye Management Inc., ExodusPoint Capital Management LP, Bank of New York Mellon Corp, Verition Fund Management LLC, Northern Trust Corp, Foster Group Inc., One68 Global Capital LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for Lumos Pharma
or or view top insider-buying stocks.

How do I buy shares of Lumos Pharma?

Shares of LUMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lumos Pharma's stock price today?

One share of LUMO stock can currently be purchased for approximately $13.44.

How much money does Lumos Pharma make?

Lumos Pharma has a market capitalization of $111.51 million and generates $940,000.00 in revenue each year. The company earns $-42,990,000.00 in net income (profit) each year or ($9.27) on an earnings per share basis.

How many employees does Lumos Pharma have?

Lumos Pharma employs 28 workers across the globe.

What is Lumos Pharma's official website?

The official website for Lumos Pharma is www.lumos-pharma.com.

Where are Lumos Pharma's headquarters?

Lumos Pharma is headquartered at 4200 MARATHON BLVD. SUITE 200, AUSTIN TX, 78756.

How can I contact Lumos Pharma?

Lumos Pharma's mailing address is 4200 MARATHON BLVD. SUITE 200, AUSTIN TX, 78756. The company can be reached via phone at 512-215-2630 or via email at [email protected]


This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.